Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MT-ND2 pseudogene 18 (MTND2P18) is classified as a pseudogene, according to the HUGO Gene Nomenclature Committee[4] and GeneCards[2]. Pseudogenes are genomic segments that closely resemble protein-coding genes but are typically non-functional due to accumulated mutations, truncation, or absence of regulatory elements. MTND2P18 is thought to be a non-functional duplicate or partial sequence of the functional mitochondrial gene MT-ND2, which itself encodes a subunit of the NADH dehydrogenase (ubiquinone) complex (Complex I)[1][2]. However, MTND2P18 itself does not encode any functional protein or known regulatory RNA and does not participate in mitochondrial respiration or cellular metabolism[2][4]. Unlike the actual MT-ND2 gene (a key component of mitochondrial Complex I that is implicated in multiple mitochondrial diseases, metabolic syndromes, and cellular energy metabolism)[1][3], MT-ND2 pseudogene 18 does not have a proven role in physiology or disease. There are no reports of this pseudogene serving as a therapeutic target, being implicated in disease processes, or interacting with drugs[2][4]. Is there something wrong? Yes: MTND2P18 is a pseudogene, not a functional drug or research target, enzyme, receptor, transporter, or transcription factor[2][4]. It does not possess any canonical molecular or disease-related activities and should not be treated as a target for drug discovery or biological modulation. Summary of key points: - MTND2P18 is a non-coding pseudogene and not a classical molecular or therapeutic target[2][4]. - It does not encode an active protein and has no known biological or disease functions. - It should not be considered in drug-target or mechanism tables. - This gene is sometimes confused with its functional counterpart (MT-ND2), but only the canonical MT-ND2 gene plays a role in mitochondrial function and human disease[1][3]. For any structured resources or annotations, MTND2P18 should be marked as a pseudogene and not as a therapeutic, physiological, or molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MT-ND2 pseudogene 18 (MTND2P18).